SCHEDULE: Versant Funds Trim LAVA Therapeutics Stake

Versant Venture Capital and Vantage funds have significantly reduced their beneficial ownership in LAVA Therapeutics N.V. through recent share sales totaling over $2.5 million.

Summary

• Versant Venture Capital VI, L.P. and Versant Vantage I, L.P., along with their affiliated entities (collectively, "Versant"), reported a reduction in their beneficial ownership of LAVA Therapeutics N.V. Common Shares.
• Between September 16 and September 18, 2025, Versant entities sold a total of 1,684,434 Common Shares.
• The aggregate proceeds from these sales amounted to approximately $2,502,240.94.
• Versant Venture Capital VI, L.P. sold 1,036,624 shares, reducing its holding to 2,370,533 shares, representing 9.0% of the outstanding common shares.
• Versant Vantage I, L.P. sold 647,810 shares, reducing its holding to 532,870 shares, representing 2.0% of the outstanding common shares.
• The combined beneficial ownership of Versant entities in LAVA Therapeutics N.V. now stands at 2,903,403 shares, or 11.0% of the 26,305,395 Common Shares outstanding as of August 8, 2025.

Sentiment

Score: 3

Explanation: The significant reduction in beneficial ownership by a major institutional investor, Versant, indicates a negative sentiment from a key stakeholder. While not a complete exit, the substantial divestment suggests a re-evaluation of the investment's prospects or a strategic reallocation of capital, which is generally viewed unfavorably by the market.

Negatives

• Significant reduction in beneficial ownership by a major institutional investor (Versant entities) could signal a loss of confidence or a strategic portfolio rebalancing.
• The sale of 1,684,434 shares over three days represents a substantial divestment, potentially increasing selling pressure on the stock.
• The weighted average sale prices declined over the three days ($1.5332, $1.4892, $1.4418), indicating a downward trend during the selling period.

Risks

• The reporting persons explicitly reserve the right to dispose of some or all of their remaining Common Shares or other securities of the Issuer at any time, which could lead to further selling pressure.
• Future investment decisions by the reporting persons will be based on various factors, including the Issuer's business, financial condition, results of operations, and prospects, implying that negative developments in these areas could trigger further divestment.

Future Outlook

The reporting persons explicitly state their intention to continuously review their investment in LAVA Therapeutics N.V. based on various factors, including the company's business, financial condition, results of operations, and prospects, as well as general economic and industry conditions. They reserve the right to acquire additional shares or dispose of their remaining holdings at any time.

Industry Context

A significant reduction in stake by a venture capital firm like Versant, which specializes in life sciences, could be interpreted in several ways within the biotechnology industry. It might indicate a strategic exit as the company matures, a re-evaluation of LAVA Therapeutics' specific pipeline or market position, or a broader shift in investment focus within Versant's portfolio. Such divestments can sometimes precede or coincide with periods of increased volatility or uncertainty for the company.

Stakeholder Impact

• Shareholders: May experience increased selling pressure and a negative perception of the company due to a major investor reducing its stake.
• Company Management: Could face questions regarding the reasons for the investor's divestment and its implications for future capital access or strategic direction.

Next Steps

• The reporting persons will continue to review their investment in LAVA Therapeutics N.V.
• The reporting persons may acquire additional shares or dispose of their remaining holdings in the future.

Key Dates

Recommendation

The substantial reduction in stake by a sophisticated institutional investor like Versant, coupled with the declining average sale prices over the selling period, signals a potential lack of confidence or a strategic exit. This action by a major holder could exert downward pressure on the stock price and suggests that the investor sees better opportunities elsewhere or has concerns about LAVA Therapeutics' near-term prospects. Investors should consider this significant divestment as a negative indicator and evaluate their own positions accordingly, potentially leading to a 'sell' recommendation.

Keywords

LAVA Therapeutics, Versant Venture Capital, Schedule 13D/A, Share Sale, Beneficial Ownership, Institutional Investor, Biotechnology, SEC Filing, Equity Stake